These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1381908)

  • 1. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.
    Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH
    Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
    Akerblom L; Hinkula J; Broliden PA; Mäkitalo B; Fridberger T; Rosen J; Villacres-Eriksson M; Morein B; Wahren B
    AIDS; 1990 Oct; 4(10):953-60. PubMed ID: 1702001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E; Chiodi F; Utter G; Norrby E
    J Immunol; 1994 Feb; 152(4):1952-9. PubMed ID: 8120399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR; Byrn R; Rosenthal K; Porter JP; Hobbs MR; Riddle L; Eastman DJ; Dowbenko D; Gregory T; Fendly BM
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1875-85. PubMed ID: 1283308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
    Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
    FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
    Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
    Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.
    Pantophlet R; Wrin T; Cavacini LA; Robinson JE; Burton DR
    Virology; 2008 Nov; 381(2):251-60. PubMed ID: 18822440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.
    Boyer V; Broly H; Souche S; Madaule P; Rossier J; Zagury D; Desgranges C
    Clin Exp Immunol; 1991 Mar; 83(3):452-9. PubMed ID: 1706239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
    Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity of three synthetic peptides from the C-terminus of HIV-1 gp 120 correlates with the fragmentation pattern obtained in FAB mass spectrometry.
    Streckert HJ; Weber C; Müller D
    Intervirology; 1993; 36(3):128-33. PubMed ID: 7512081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the principal neutralization site of HIV-1.
    Ghiara JB; Stura EA; Stanfield RL; Profy AT; Wilson IA
    Science; 1994 Apr; 264(5155):82-5. PubMed ID: 7511253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.